tbuckley/cabot-search huggingface dataset:
AB0303 Ultrasound aspect of posterior tibial tendon in rheumatoid arthritis
Authors: S. Afilal, H. rkain, S. fellous, L. tahiri, N. alami, R. Guieu, Y. Jammes, F. Allali, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Posterior tibial tendon involvement is common in rheumatoid arthritis. Ultrasound has an important place in the examination of this tendon. <h3>Objectives</h3> Evaluate the prevalence of ultrasound signs of posterior tibial tendon involvement in rhumatoid arthritis. <h3>Methods</h3> This is a cross-sectional study that included fourteen consecutive patients (100% female, mean age 55.3 years) with rhumatoid arthritis (median duration of progression of 13.5 years, mean specialised care of 2.1 years). A grey and Doppler ultrasound study was performed on affected feet, looking for effusion, thickening or corporal thinning, hypoechoic aspect, fissures, and Doppler activity in the posterior tibial tendon. <h3>Results</h3> 28 feet were studied with ultrasound evaluation of the posterior tibial tendon. Figure 1 illustrates the prevalence of the pathological aspects of the posterior tibial found on ultrasound examination. <h3>Conclusions</h3> This study illustrates the different pathological aspects of the posterior tibial tendon. It highlights the high prevalence of this tendinopathy in the rheumatoid foot. Ultrasound allows accurate assessment of this tendon in RA patients. A large-scale study compared with a control group is necessary to better interpret and complete these preliminary results. <h3>Disclosure of Interest</h3> None declared
Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography
Authors: Stephen Salloway
Journal: JAMA Neurology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Thomas Hindson and His Discovery of Ascorbic Acid to Treat Prickly Heat
Authors: Manthan Patel, Varun Ayyaswami, Arpan V. Prabhu
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
The Genetic Architecture of Diet‐Induced Hepatic Fibrosis in Mice
Authors: Simon T. Hui, Zeyneb Kurt, Iina Tuominen, Frode Norheim, Richard C.Davis, Calvin Pan, Darwin L. Dirks, Clara E. Magyar, Samuel W. French, Karthickeyan Chella Krishnan, Simon Sabir, Francisco Campos‐Pérez, Nahum Méndez‐Sánchez, Luis Macías‐Kauffer, Paola León‐Mimila, Samuel Canizales‐Quinteros, Xia Yang, Simon W. Beaven, Adriana Huertas‐Vazquez, Aldons J. Lusis
Journal: Hepatology (2018)

We report the genetic analysis of a “humanized” hyperlipidemic mouse model for progressive nonalcoholic steatohepatitis (NASH) and fibrosis. Mice carrying transgenes for human apolipoprotein E*3‐Leiden and cholesteryl ester transfer protein and fed a “Western” diet were studied on the genetic backgrounds of over 100 inbred mouse strains. The mice developed hepatic inflammation and fibrosis that was highly dependent on genetic background, with vast differences in the degree of fibrosis. Histological analysis showed features characteristic of human NASH, including macrovesicular steatosis, hepatocellular ballooning, inflammatory foci, and pericellular collagen deposition. Time course experiments indicated that while hepatic triglyceride levels increased steadily on the diet, hepatic fibrosis occurred at about 12 weeks. We found that the genetic variation predisposing to NASH and fibrosis differs markedly from that predisposing to simple steatosis, consistent with a multistep model in which distinct genetic factors are involved. Moreover, genome‐wide association identified distinct genetic loci contributing to steatosis and NASH. Finally, we used hepatic expression data from the mouse panel and from 68 bariatric surgery patients with normal liver, steatosis, or NASH to identify enriched biological pathways. Conclusion: The pathways showed substantial overlap between our mouse model and the human disease.
A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension
Authors: Anna R. Hemnes, Anandharajan Rathinasabapathy, Eric A. Austin, Evan L. Brittain, Erica J. Carrier, Xinping Chen, Joshua P. Fessel, Candice D. Fike, Peter Fong, Niki Fortune, Robert E. Gerszten, Jennifer A. Johnson, Mark Kaplowitz, John H. Newman, Robert Piana, Meredith E. Pugh, Todd W. Rice, Ivan M. Robbins, Lisa Wheeler, Chang Yu, James E. Loyd, James West
Journal: European Respiratory Journal (2018)

Pulmonary arterial hypertension (PAH) is a deadly disease with no cure. Alternate conversion of angiotensin II (AngII) to angiotensin-(1–7) (Ang-(1–7)) by angiotensin-converting enzyme 2 (ACE2) resulting in Mas receptor (Mas1) activation improves rodent models of PAH. Effects of recombinant human (rh) ACE2 in human PAH are unknown. Our objective was to determine the effects of rhACE2 in PAH. We defined the molecular effects of Mas1 activation using porcine pulmonary arteries, measured AngII/Ang-(1–7) levels in human PAH and conducted a phase IIa, open-label pilot study of a single infusion of rhACE2 (GSK2586881, 0.2 or 0.4 mg·kg −1 intravenously). Superoxide dismutase 2 (SOD2) and inflammatory gene expression were identified as markers of Mas1 activation. After confirming reduced plasma ACE2 activity in human PAH, five patients were enrolled in the trial. GSK2586881 was well tolerated with significant improvement in cardiac output and pulmonary vascular resistance. GSK2586881 infusion was associated with reduced plasma markers of inflammation within 2–4 h and increased SOD2 plasma protein at 2 weeks. PAH is characterised by reduced ACE2 activity. Augmentation of ACE2 in a pilot study was well tolerated, associated with improved pulmonary haemodynamics and reduced markers of oxidant and inflammatory mediators. Targeting this pathway may be beneficial in human PAH.
Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas
Authors: Antonio Macciò, Clelia Madeddu
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Health Impacts of Citywide and Localized Power Outages in New York City
Authors: Christine Dominianni, Kathryn Lane, Sarah Johnson, Kazuhiko Ito, Thomas Matte
Journal: Environmental Health Perspectives (2018)

Previous studies investigated potential health effects of large-scale power outages, including the massive power failure that affected the northeastern United States and Ontario, Canada, in August 2003, and outages associated with major storms. However, information on localized outages is limited.The study sought to examine potential health impacts of citywide and localized outages in New York City (NYC).Along with the citywide 2003 outage, localized outages in July 1999 and July 2006 were identified. We additionally investigated localized, warm- and cold-weather outages that occurred in any of 66 NYC electric-grid networks during 2002–2014 using New York State Public Service Commission data. Mortality and hospitalizations were geocoded and linked to the networks. Associations were estimated using Poisson time-series regression, including examining distributed lags and adjusting for temperature and temporal trends. Network-specific estimates were pooled by season.Respiratory disease hospitalizations were associated with the 2006 localized outage [cumulative relative risk [CRR] over 0–1 lag day, lag01=2.26 (95% confidence interval [CI]: 1.08, 4.74)] and the 2003 citywide outage, but not with other localized, warm-weather outages. Renal disease hospitalizations were associated with the 2003 citywide outage, and with localized, warm-weather outages, pooled across networks [RR at lag3=1.16 (95% CI: 1.00, 1.34)], but not the 2006 localized outage. All-cause mortality was positively associated with the 1999, 2003, and 2006 outages (significant for the 2003 outage only), but not with other localized, warm-weather outages. Localized, cold-weather outages were associated with all-cause mortality [lag01 CRR=1.06 (95% CI: 1.01, 1.12)] and cardiovascular disease hospitalizations [lag01 CRR=1.14 (95% CI: 1.03, 1.26)], and fewer respiratory disease hospitalizations [lag03 CRR=0.77 (95% CI: 0.61, 0.97)].Localized outages may affect health. This information can inform preparedness efforts and underscores the public health importance of ensuring electric grid resiliency to climate change. https://doi.org/10.1289/EHP2154.
HIV-1 latent reservoir size and diversity are stable following brief treatment interruption
Authors: D. Brenda Salantes, Yu Zheng, Felicity Mampe, Tuhina Srivastava, Subul Beg, Jun Lai, Jonathan Z. Li, Randall L. Tressler, Richard A. Koup, James Hoxie, Mohamed Abdel-Mohsen, Scott Sherrill-Mix, Kevin McCormick, E. Turner Overton, Frederic D. Bushman, Gerald H. Learn, Robert F. Siliciano, Janet M. Siliciano, Pablo Tebas, Katharine J. Bar
Journal: Journal of Clinical Investigation (2018)

BACKGROUND. The effect of a brief analytical treatment interruption (ATI) on the HIV-1 latent reservoir of individuals who initiate antiretroviral therapy (ART) during chronic infection is unknown.
Meckel’s diverticulum on third-generation video capsule endoscopy: intradiverticular ulcer, ectopic gastric mucosa, and active bleeding
Authors: Jean-Philippe Le Mouel, Julie Morvan, Mathurin Fumery, Sami Hakim, Richard Delcenserie, Denis Chatelain, Eric Nguyen-Khac
Journal: Endoscopy (2018)

A 29-year-old man presented with acute rectal bleeding causing hemorrhagic shock. The patient had presented with a similar episode of digestive bleeding 4 years previously, with no diagnosis being found. His physical examination did not reveal any clinical abnormalities. Gastroscopy, colonoscopy, and abdominal computed tomography angiography (CTA) were normal. Small-bowel video capsule endoscopy revealed an ileal diverticular orifice, with the double-lumen sign. After passage of the capsule into the diverticulum, an ulcer with a visible vessel (Forrest IIa) was observed at the bottom of the diverticulum, located next to a patch of heterotopic gastric mucosa. During this examination, active bleeding was seen from this area of ulceration ([Fig. 1]; [Video 1]).
Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States
Authors: Dima Mazen Qato, Katharine Ozenberger, Mark Olfson
Journal: JAMA (2018)

Prescription medications are increasingly used among adults in the United States and many have a potential for causing depression.To characterize use of prescription medications with depression as a potential adverse effect and to assess associations between their use and concurrent depression.Five 2-year cycles (2005-2006 through 2013-2014) of the National Health and Nutrition Examination Survey, representative cross-sectional surveys of US adults aged 18 years or older, were analyzed for use of medications with depression as a potential adverse effect. Multivariable logistic regression examined associations between use of these medications and concurrent depression. Analyses were performed among adults overall, excluding antidepressant users, and among adults treated with antidepressants and with hypertension.Prescription medications with depression as a potential adverse effect (listed in Micromedex).Prevalence of any use and concurrent use of medications with a potential to cause depression and prevalence of depression (PHQ-9 score ≥10).The study included 26 192 adults (mean age, 46.2 years [95% CI, 45.6-46.7]; women, 51.1%) and 7.6% (95% CI, 7.1%-8.2%) reported depression. The overall estimated prevalence of use of medications with depression as an adverse effect was 37.2%, increasing from 35.0% (95% CI, 32.2%-37.9%) in the cycle years 2005 and 2006 to 38.4% (95% CI, 36.5%-40.3%) in 2013 and 2014 (P for trend = .03). An estimated 6.9% (95% CI, 6.2%-7.6%) reported use of 3 or more concurrent medications with a potential for depression as an adverse effect in 2005 and 2006 and 9.5% (95% CI, 8.4%-10.7%) reported such use in 2013 and 2014 (P for trend = .001). In adjusted analyses excluding users of antidepressants, the number of medications used with depression as possible adverse effects was associated with increased prevalence of concurrent depression. The estimated prevalence of depression was 15% for those reporting use of 3 or more medications with depression as an adverse effect vs 4.7% for those not using such medications (difference, 10.7% [95% CI, 7.2%-14.1%]). These patterns persisted in analyses restricted to adults treated with antidepressants, among hypertensive adults, and after excluding users of any psychotropic medication.In this cross-sectional survey study, use of prescription medications that have depression as a potential adverse effect was common. Use of multiple medications was associated with greater likelihood of concurrent depression.
In vivo tracking and quantification of inhaled aerosol using magnetic particle imaging towards inhaled therapeutic monitoring
Authors: Zhi Wei Tay, Prashant Chandrasekharan, Xinyi Yedda Zhou, Elaine Yu, Bo Zheng, Steven Conolly
Journal: Theranostics (2018)

Pulmonary delivery of therapeutics is attractive due to rapid absorption and non-invasiveness but it is challenging to monitor and quantify the delivered aerosol or powder. Currently, single-photon emission computed tomography (SPECT) is used but requires inhalation of radioactive labels that typically have to be synthesized and attached by hot chemistry techniques just prior to every scan. Methods: In this work, we demonstrate that superparamagnetic iron oxide nanoparticles (SPIONs) can be used to label and track aerosols in vivo with high sensitivity using an emerging medical imaging technique known as magnetic particle imaging (MPI). We perform proof-of-concept experiments with SPIONs for various lung applications such as evaluation of efficiency and uniformity of aerosol delivery, tracking of the initial aerosolized therapeutic deposition in vivo, and finally, sensitive visualization of the entire mucociliary clearance pathway from the lung up to the epiglottis and down the gastrointestinal tract to be excreted. Results: Imaging of SPIONs in the lung has previously been limited by difficulty of lung imaging with magnetic resonance imaging (MRI). In our results, MPI enabled SPION lung imaging with high sensitivity, and a key implication is the potential combination with magnetic actuation or hyperthermia for MPI-guided therapy in the lung with SPIONs. Conclusion: This work shows how magnetic particle imaging can be enabling for new imaging and therapeutic applications of SPIONs in the lung.
Identification of Tracheobronchial Tree Calcifications Using Molecular Imaging Probes
Authors: Abdullah Al-Zaghal, Thomas J. Werner, Poul F. Høilund-Carlsen, Abass Alavi
Journal: Clinical Nuclear Medicine (2018)

Tracheobronchial calcifications are common in adults and considered as a physiological process of aging with no clinical significance in otherwise asymptomatic, healthy individuals. We are presenting a case of tracheobronchial tree calcifications as detected on F-NaF PET/CT in a 75-year-old woman. Many previous publications have reported the accumulation of NaF in extraosseous organs; these observations further set new directions in the evaluation of the metabolic activity of macrocalcification and microcalcification using molecular imaging probes.
SAT0185 Certolizumab pegol serum levels ≥20 mg/l are associated with improvement in das28 in rheumatoid arthritis patients. data from the nor-dmard study
Authors: J. E. Gehin, S. W. Syversen, D. J. Warren, G. L. Goll, J. Sexton, E. K. Strand, T. K. Kvien, N. Bolstad, E. Lie
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Measurement of serum drug levels can help clinicians tailor treatment with TNF-inhibitors. An association between certolizumab pegol (CP) serum levels and treatment response in rheumatoid arthritis (RA) patients (pts) has previously been demonstrated in a prospective observational study (1). These results need to be confirmed in other studies, with particular focus on finding an optimal therapeutic serum level for CP. <h3>Objectives:</h3> To examine the association between serum CP drug levels and treatment response in RA pts and to identify a therapeutic target level. <h3>Methods:</h3> Patients with a clinical diagnosis of RA starting standard treatment with CP included in the NOR-DMARD registry with biobank sample at 3 months follow-up, were included in the present analyses. Serum drug levels (non-trough) were analysed with an in-house immunofluorometric assay automated on the AutoDELFIA immunoassay platform. We studied association between serum CP level and &amp;x25B3;DAS28 and EULAR good/moderate response at 3 months by multivariable linear and logistic regression analyses, respectively, adjusting for age, sex and prior bDMARD (Y/N). <h3>Results:</h3> In 91 included patients, median serum drug level at 3 months follow up was 34.7 mg/L (17.6–44.6). Response data were available in 81/91 patients. Serum CP level ≥20 mg/L was associated with greater improvement in DAS28 at 3 months (β=0.89 (95% CI 0.03–1.74), P=0.04. 44.4 % of pts with CP level &lt;20 mg/L achieved EULAR response after 3 months treatment, while 73.5 % of pts with CP level 20–40 mg/L and 55.2 % with ≥40 mg/L were responders. However, the difference in EULAR response between pts with CP level ≥20 vs. &lt;20 mg/L did not reach statistical significance (OR 1.5 (95% CI 0.5–5.1), P=0.48). <h3>Conclusions:</h3> Certolizumab serum levels ≥20 mg/L were associated with DAS28 improvement, but not significantly with EULAR response after 3 months treatment in RA pts. We suggest 20 mg/L as a lower target limit for non-trough CP samples in RA-patients. No additional benefit of having a certolizumab level over 40 mg/L was observed. <h3>Reference</h3> [1]Jani M, et al. AnnRheum Dis2017;76(1):208–13. <h3>Disclosure of Interest:</h3> J. E. Gehin Consultant for: Roche, S. Syversen Consultant for: Roche, D. Warren: None declared, G. Goll Consultant for: Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Eli Lilly, Novartis, Pfizer, MSD, Roche, UCB, J. Sexton: None declared, E. Strand Consultant for: Pfizer, T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celgene, Celltrion, Eli Lilly, Epirus, Hospira, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz, UCB, N. Bolstad Consultant for: Pfizer, Orion Pharma, Napp pharmaceuticals, Takeda, Roche, E. Lie: None declared